Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Genmab
AstraZeneca
Beijing Biotech
Gilead Sciences
National Institutes of Health Clinical Center (CC)
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Artiva Biotherapeutics, Inc.
M.D. Anderson Cancer Center
AvenCell Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Beijing Biotech
Beijing Biotech
BriaCell Therapeutics Corporation
Medical University of South Carolina
City of Hope Medical Center
ExCellThera inc.
National Institutes of Health Clinical Center (CC)
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Centre Oscar Lambret
M.D. Anderson Cancer Center
Beijing Biotech
St. Jude Children's Research Hospital
Chinese PLA General Hospital
Mayo Clinic
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Ossium Health, Inc.
Intima Bioscience, Inc.
Intima Bioscience, Inc.
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech